Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 17, 2023

Patient Likelihood of Being Helped or Harmed as a Tool to Weigh Efficacy and Safety of the Different CDK4/6 Inhibitors in Metastatic Breast Cancer



Additional Info

Disclosure statements are available on the authors' profiles:

The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
EClinicalMedicine 2023 Feb 01;56(xx)101824, L Mastrantoni, A Orlandi, A Palazzo, G Garufi, A Fabi, G Daniele, D Giannarelli, G Tortora, E Bria

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading